Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *
				Welcome to SIN International
NEWS	1			Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG	06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG	06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG	13	CA/CAplus enhanced with additional kind codes for granted
				patents
NEWS	5	AUG	20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG	27	Full-text patent databases enhanced with predefined
				patent family display formats from INPADOCDB
NEWS		AUG		USPATOLD now available on STN
NEWS	8	AUG	28	CAS REGISTRY enhanced with additional experimental
	_			spectral property data
NEWS	9	SEP	0.7	STN AnaVist, Version 2.0, now available with Derwent
NEWS	2.0	SEP	1.0	World Patents Index FORIS renamed to SOFIS
NEWS		SEP		INPADOCDB enhanced with monthly SDI frequency
NEWS		SEP		CA/CAplus enhanced with monthly SDI frequency
MEMP	12	JEE	1,	1967-1998
NEWS	13	SEP	17	CAplus coverage extended to include traditional medicine
				patents
NEWS		SEP		EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT	02	CA/CAplus enhanced with pre-1907 records from Chemisches
NEWS	16	OCT	10	Zentralblatt BEILSTEIN updated with new compounds
NEWS		NOA		Derwent Indian patent publication number format enhanced
NEWS		NOV		WPIX enhanced with XML display format
NEWS		NOV		ICSD reloaded with enhancements
NEWS			04	LINPADOCDB now available on STN
NEWS			14	BEILSTEIN pricing structure to change
NEWS	22	DEC	17	USPATOLD added to additional database clusters
NEWS	23	DEC	17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC	17	DGENE now includes more than 10 million sequences
NEWS	25	DEC	17	TOXCENTER enhanced with 2008 MeSH vocabulary in
				MEDLINE segment
NEWS		DEC		MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS		DEC		CA/CAplus enhanced with new custom IPC display formats
NEWS	28	DEC	17	STN Viewer enhanced with full-text patent content
NELLO	00	77.11	0.0	from USPATOLD
NEWS NEWS		JAN JAN		STN pricing information for 2008 now available
MEMP	30	UMIN	10	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN	28	USPATFULL, USPAT2, and USPATOLD enhanced with new
				custom IPC display formats
NEWS		JAN		MARPAT searching enhanced
NEWS	33	JAN	28	USGENE now provides USPTO sequence data within 3 days
NEWS	3.4	JAN	29	of publication TOXCENTER enhanced with reloaded MEDLINE segment
MEMP	34	OMIN	40	TONGERIEN EIMENCEU WITH TETORGEG MEDEINE SEGMENT

NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements NEWS 36 FEB 08 STN Express, Version 8.3, now available

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 19:14:54 ON 19 FEB 2008

=> file reg

 COST IN U.S. DOLLARS
 SINCE FILE
 TOTAL

 FULL ESTIMATED COST
 0.21
 0.21

FILE 'REGISTRY' ENTERED AT 19:15:03 ON 19 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by ${\tt InfoChem.}$

STRUCTURE FILE UPDATES: 18 FEB 2008 HIGHEST RN 1004360-55-7
DICTIONARY FILE UPDATES: 18 FEB 2008 HIGHEST RN 1004360-55-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

_ \

Uploading C:\Program Files\Stnexp\Queries\10518714.str



```
chain nodes :
 11 12 13 14
 ring nodes :
 1 2 3 4 5 6 8 17 18 19 20 21 22 23 24 25 26 27 28 29 30
 chain bonds :
 11-12 11-14 12-13 12-17
 ring bonds :
 1-2 1-6 1-8 2-3 3-4 4-5 4-8 5-6 17-18 17-22 18-19 18-27 19-20 19-30
 20-21 21-22 21-23 22-26 23-24 24-25 25-26 27-28 28-29 29-30
 exact/norm bonds :
 1-2 1-6 1-8 2-3 3-4 4-5 4-8 5-6 11-12 11-14 12-13 12-17 17-18 17-22
 19-20 20-21
 normalized bonds :
 18 - 19 \quad 18 - 27 \quad 19 - 30 \quad 21 - 22 \quad 21 - 23 \quad 22 - 26 \quad 23 - 24 \quad 24 - 25 \quad 25 - 26 \quad 27 - 28 \quad 28 - 29 \quad 29 - 30 \quad 20 - 20 \quad 20 -
 isolated ring systems :
containing 1 : 17 :
```

G1:C, H


G2:C,O,S

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 8:Atom 11:CLASS 12:CLASS
13:CLASS 14:CLASS 16:CLASS 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 22:Atom 23:Atom 25:Atom 25:Atom 27:Atom 28:Atom 29:Atom 30:Atom

L1 STRUCTURE UPLOADED

=> d 11 L1 HAS NO ANSWERS

STR



G2 C, O, S

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 19:15:35 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -839 TO ITERATE

100.0% PROCESSED 839 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01 FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE** PROJECTED ITERATIONS: 15043 TO 18517 PROJECTED ANSWERS: 1 TO

L2 1 SEA SSS SAM L1

=> s 11 full FULL SEARCH INITIATED 19:15:39 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 16710 TO ITERATE

100.0% PROCESSED 16710 ITERATIONS 28 ANSWERS SEARCH TIME: 00.00.01

L3 28 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 19:15:44 ON 19 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1936), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Feb 2008 VOL 148 ISS 8 FILE LAST UPDATED: 18 Feb 2008 (20080218/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicv.html

=> s 13 full L4 1 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:41467 CAPLUS

DOCUMENT NUMBER: 140:94180

TITLE: Preparation of new quinuclidine amide derivatives for

therapeutic uses as antagonists of M3 muscarinic

receptors

INVENTOR(S): Prat Quinones, Maria

PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain

SOURCE: PCT Int. Appl., 65 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English FAMILY ACC. NUM. COUNT:

PATENT INFORMATION: DAMENIE NO

	PATENT NO.								APPLICATION NO.								
							20040115		WO 2003-EP6708								
												BG, BR,					
												E, ES,					
												KP.					
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	M	i, M	WX,	MZ,	NI,	NO,	NZ,	OM,
		PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE	E, SC	s, sk,	SL,	ТJ,	TM,	TN,	TR,
												A, ZM,					
	RW:											z, UG,					
												I, CY,					
												, PT,					
												7, ML,					
ES	2204			A1 20040416				ES 2002-1539						20020702			
ES	2204295				B1 20050801												
CA	2492535				A1 20040115			CA 2003-2492535 AU 2003-242757 EP 2003-762514						20030625			
AU	2003242757				A1 20040123			AU 2003-242757						20030625			
EP	1519933				A1 20050406			EP 2003-762514 GB, GR, IT, LI, LU,					20030625				
	R:																
	IE, SI, LT,				LV, F1, RO, MK,				CY, AL, TR, BG, CZ,					EE, HU, SK			
BK	BK 2003012216				A 20030412					BR 2003-12216					20030625		
CIN	UN 10/8010				T 20051005				TP 2004-518575					20030623			
NZ	N7 537341				A 20051110					BR 2003-12216 CN 2003-820648 JP 2004-518575 NZ 2003-537341 RU 2005-102585					20030625		
DII	DII 231/306					C2 20080110				RII 2005-102585					20030625		
MY	MY 2004PA12271					a 20050418				MX 2004-PA12271					20030023		
										ZA 2004-10404							
TN	TN 2004DN04140						20061229			TN	N 2004-DN4140			20041227			
NO	IN 2004DN04140 NO 2005000164 US 2006167042 RIORITY APPLN. INFO.:						2005	20050404		NO	2005-164				20050112		
US	US 2006167042				A1		20060727			US 2005-518714			20050801		801		
PRIORIT	RIORITY APPLN. INFO.:									ES	2002	2-1539	9		A 2	0020	702
										WO	2003	-EP6	708		W 2	0030	625
OTHER S	HER SOURCE(S):				MARI	PAT	140:	94180									
GI																	

Ph II

AB N-quinuclidinyl amides, such as I [R1 = H, alkyl; R3 = furyl, thienyl, phenyl; R4 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylmethyl, Ph, benzyl, phenethyl, furyl, thienyl; R5 = H, OH, Me, CH2OHI, were prepared for use in therapy as antagonists of M3 muscarinic receptors. These amides are claimed for use in the treatment of respiratory, urol. or gastrointestinal pathol. conditions and diseases susceptible to amelioration by antagonism of M3 muscarinic receptors. Thus, amide II was prepared in 63.1% yield via an amidation reaction of (3R)-aminoquinuciding with 2-phenylhexanoic acid in DMF and CHC13. The prepared N-quinuclidinyl amides were assayed for human muscarinic receptor binding activity and for effect on bronchial response to i.v. acetylcholine challenge in guinea pigs. Tablet, liquid inhalant, powder inhalant, and inhalation aerosol pharmaceutical commons of the amides were presented.

IT 644468-35-9P 644468-40-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of N-quinuclidinyl amides for use in pharmaceutical compns. as M3 muscarinic receptor antagonists)

RN 644468-35-9 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.

RN 644468-40-6 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-y1- (CA INDEX NAME)

Absolute stereochemistry.

644468-75-TP 644468-77-9P 644468-79-1P 644468-80-4P 644468-82-6P 644468-84-8P 644468-96-2P 644468-97-3P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

644468-22-4P 644468-34-8P 644468-39-3P 644468-71-3P 644468-72-4P 644468-73-5P

(preparation of N-quinuclidinyl amides for use in pharmaceutical compns. as

M3 muscarinic receptor antagonists)

- RN 644468-22-4 CAPLUS
- CN 9H-Xanthene-9-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-y1-N-methyl-(CA INDEX NAME)

Absolute stereochemistry.

- RN 644468-34-8 CAPLUS
- CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropy1)-3-[(9H-xanthen-9ylcarbonyl)amino]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PhO

• Br -

- RN 644468-39-3 CAPLUS
- CN 1-Azoniabicyclo[2.2.2]octane, 1-(cyclohexylmethyl)-3-[(9H-xanthen-9-ylcarbonyl)amino]-, (3S)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 644468-38-2

CMF C28 H35 N2 O2
Absolute stereochemistry.

CM 2

CRN 14477-72-6 CMF C2 F3 O2

RN 644468-71-3 CAPLUS

CN 9H-Xanthene-9-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

RN 644468-72-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-methyl-3-[(9H-xanthen-9-ylcarbonyl)amino]-, bromide (9CI) (CA INDEX NAME)

• Br-

RN 644468-73-5 CAPLUS
CN 1-Azoniabicyclo[2,2,2]octane, 1-(3-phenoxypropyl)-3-[(9H-xanthen-9-yicarbonyl)amino]-, bromide (9CI) (CA INDEX NAME)

• Br-

RN 644468-75-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-(2-propenyl)-3-[(9H-xanthen-9-ylcarbonyl)amino]-, (3S)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 644468-74-6 CMF C24 H27 N2 O2

Absolute stereochemistry.

CM 2

CRN 14477-72-6 CMF C2 F3 O2

CN

RN 644468-77-9 CAPLUS

1-Azoniabicyclo[2.2.2]octane, 1-heptyl-3-[(9H-xanthen-9-ylcarbonyl)amino]-, (3S)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 644468-76-8 CMF C28 H37 N2 O2

Absolute stereochemistry.

CM 2

CRN 14477-72-6 CMF C2 F3 O2

RN 644468-79-1 CAPLUS CN 1-Azoniabicvclo[2.2

1-Azoniabicyclo[2.2.2]octane, 1-(3-cyclohexylpropyl)-3-[(9H-xanthen-9-ylcarbonyl)amino]-, (35)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 644468-78-0 CMF C30 H39 N2 O2 Absolute stereochemistry.

CM 2

CRN 14477-72-6 CMF C2 F3 O2

RN 644468-80-4 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-(3-phenoxypropyl)-3-[(9H-xanthen-9-ylcarbonyl)amino]-, bromide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Br⁻

RN 644468-82-6 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 1-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]-3-[(9H-xanthen-9-ylcarbonyl)amino]-, (3S)-, salt with trifluoroacetic acid (1:1) (9C1) (CA INDEX NAME)

CM 1

CRN 644468-81-5 CMF C34 H39 N2 O3 Absolute stereochemistry.

CM 2

CRN 14477-72-6 CMF C2 F3 O2

RN 644468-84-8 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 1-[5-(2,6-dimethylphenoxy)pentyl]-3-[(9H-xanthen-9-ylcarbonyl)amino]-, (3S)-, salt with trifluoroacetic acid (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 644468-83-7 CMF C34 H41 N2 O3

Absolute stereochemistry.

CRN 14477-72-6 CMF C2 F3 O2

RN 644468-96-2 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[methyl(9H-xanthen-9-ylcarbonyl)amino]-1-[3-(1H-pyrrol-1-yl)propyl]-, bromide, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Br -

RN 644468-97-3 CAPLUS

CN

1-Azoniabicyclo[2.2.2]octane, 1-[3-([1,1'-biphenyl]-4-yloxy)propyl]-3-[methyl(9H-xanthen-9-ylcarbonyl)amino]-, chloride, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

(FILE 'HOME' ENTERED AT 19:14:54 ON 19 FEB 2008)

FILE 'REGISTRY' ENTERED AT 19:15:03 ON 19 FEB 2008

STRUCTURE UPLOADED

L2 1 S L1 L3 28 S L1 FULL

FILE 'CAPLUS' ENTERED AT 19:15:44 ON 19 FEB 2008 1 S L3 FULL L4

=> log y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 5.93 184.50

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL SESSION ENTRY CA SUBSCRIBER PRICE -0.80 -0.80

STN INTERNATIONAL LOGOFF AT 19:16:15 ON 19 FEB 2008